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ABSTRACT
Epidermal Growth Factor Receptor (EGFR), a member of the ErbB family of 
receptor tyrosine kinase (RTK) proteins, is aberrantly expressed or deregulated in 
tumors and plays pivotal roles in cancer onset and metastatic progression. ZNF216 
gene has been identified as one of Immediate Early Genes (IEGs) induced by 
RTKs. Overexpression of ZNF216 protein sensitizes 293 cell line to TNF-α induced 
apoptosis. However, ZNF216 overexpression has been reported in medulloblastomas 
and metastatic nasopharyngeal carcinomas. Thus, the role of this protein is still not 
clearly understood. In this study, the inverse correlation between EGFR and ZNF216 
expression was confirmed in various human cancer cell lines differently expressing 
EGFR. EGF treatment of NIH3T3 cells overexpressing both EGFR and ZNF216 (NIH3T3-
EGFR/ZNF216), induced a long lasting activation of EGFR in the cytosolic fraction 
and an accumulation of phosphorylated EGFR (pEGFR) more in the nuclear than in 
the cytosolic fraction compared to NIH3T3-EGFR cells. Moreover, EGF was able to 
stimulate an increased expression of ZNF216 in the cytosolic compartment and its 
nuclear translocation in a time-dependent manner in NIH3T3-EGFR/ZNF216. A similar 
trend was observed in A431 cells endogenously expressing the EGFR and transfected 
with Znf216. The increased levels of pEGFR and ZNF216 in the nuclear fraction of 
NIH3T3-EGFR/ZNF216 cells were paralleled by increased levels of phospho-MAPK and 
phospho-Akt. Surprisingly, EGF treatment of NIH3T3-EGFR/ZNF216 cells induced a 
significant increase of apoptosis thus indicating that ZNF216 could sensitize cells to 
EGF-induced apoptosis and suggesting that it may be involved in the regulation and 
effects of EGFR signaling.
INTRODUCTION
Cellular signaling plays a very important role to 
regulate cell proliferation, survival and differentiation. 
The pathways involved in these cellular effects and the 
interactions among them are finely regulated with a high 
degree of specificity. Alterations of the cellular signaling 
could lead to pathology, as occurs in tumors. A very 
important role for the intracellular communication is played 
by cell-surface receptors which provide the interaction 
of cells with other cells and with the extracellular 
environment. One of the best characterized families of 
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these cell-surface receptors is the ErbB family of receptor 
tyrosine kinases, that includes Epidermal Growth Factor 
Receptor (EGFR, ErbB1), ErbB2, ErbB3, and ErbB4. 
These receptors regulate a complex signaling network that 
impacts several cellular processes such as proliferation, 
survival, angiogenesis, and metastasis in many cancers.
EGFR is abnormally activated in many epithelial 
cells and its signaling can provide substantial advantage in 
tumor cells survival [1]. Abnormalities in gene expression, 
due to gene amplification, overexpression or mutations and 
alterations in signaling pathways downstream of the EGFR, 
contribute to the progression, invasion, and maintenance 
of the malignant phenotype in several human cancers, 
including head and neck, prostate, breast, bladder, ovarian, 
renal, colon, NSCLC [2]. All these findings support 
the role of EGFR as an important target for therapeutic 
intervention. Moreover, our group detected specific 
immune responses against all ErbB receptors in tumor 
patients with different epithelial malignancies including 
prostate cancer [3], and the presence of an autocrine loop 
in breast [4] and thyroid transformed cells [5]. 
The EGFR is activated by binding four different 
ligands, most commonly EGF and TGF-α. After ligand 
binding it forms homodimeric or heterodimeric complexes 
with other members of the ErbB family of receptors, 
preferably with ErbB2 [6].
Ligand binding and dimerization cause 
autophosphorylation of the intracytoplasmic domains 
and activation of the intracellular molecules such as the 
MAPK/ERK and the phosphoinositide-3 kinase (PI3K) 
pathways which regulate proliferation and cell survival [7]. 
After autophosphorylation causing its activation, EGFR 
is ubiquitinated and targeted for internalization [8, 9]. 
Once internalized, receptor complexes remain active, but 
eventually are either degraded within the lysosomes or 
recycled to the plasma membrane [10]. However, many 
studies demonstrated that EGFR could be shuttled from 
the plasma membrane to the nucleus after EGF stimulation 
[11] where it acts as a transcription co-factor [12–17]. In 
fact, interestingly, the EGFR lacks a DNA-binding domain 
and the nuclear EGFR physically interacts with other 
transcriptional molecules, such as the Signal Transducer 
and Activator of Transcription 3 (STAT3) to activate gene 
expression [14]. This interplay between EGFR activation, 
degradation and recycling, produces complex signaling 
layers interconnected by regulators with time and context 
restrictions (e.g., ligand type, gene transcription) that 
dictate EGFR-dependent responses (proliferation, survival, 
adhesion, differentiation, and migration) [18]. Thus, the 
different biological effects induced by activated EGFR and 
the regulation of its signaling may be due to its intracellular 
trafficking [19], to the expression of different genes, to 
modulation of individual pathways downstream of receptor 
activation and to its nuclear translocation [20, 21].
Our interest in zinc finger protein 216 (ZNF216) 
was attributable to its involvement in the interaction 
through its A20-like zinc finger domain with polyubiquitin 
chains and association with the 26S proteasome [22] 
and to the finding of its transcription as an immediate 
early gene (IEG) after activation of the tyrosine kinase 
receptors [23]. The ZNF216 expression is associated with 
atrophy in skeletal muscles, acting as a shuttle factor of 
ubiquitinylated proteins targeted to the 26S proteasome 
for degradation and the ZNF-A20 domain is required 
for binding to polyubiquitin [22]. These results support 
ZNF216’s status as an atrogene. The A20 ZNF domain of 
ZNF216 and the UBA (Ub-associated domain) of the p62 
protein are able to form an Ub-mediated ternary complex 
through independent interactions with a single Ub [24].
The ZNF216 gene was previously characterized 
during a study carried out to identify candidate genes 
for Autosomal Recessive Nonsyndromic Hearing Loss 
(ARNSHL) that are located in the DFNB7/11 interval 
in 9q13-q21 [25]. However, despite the position of 
ZNF216 on the human chromosome implicating a causal 
relationship to hearing loss, it could not be validated as a 
candidate. It has been reported that ZNF216 may inhibit 
TNF-induced NF-kB activation and sensitize cells to 
TNF-induced apoptosis [26]. In another study aimed 
at identifying differences in gene expression between 
medulloblastoma, a childhood brain tumor, and foetal brain, 
ZNF216 has been found expressed mostly in tumor tissue 
[27]. Moreover, ZNF216 has been found to be up-regulated 
in metastatic nasopharyngeal carcinoma cells compared to 
non-metastatic cells [28]. In addition, it has been shown 
that ZNF216 is among the 352 hepatic genes Keap-Nrf2-
dependent induced by the D3T (3H-1,2-dithiole-3-thione), 
a detoxifying enzyme that enhances detoxication of 
environmental carcinogens and protect against neoplasia 
[29]. ZNF216 was found to be down-regulated together 
with EGFR in a mouse model of human EDA (Anhidrotic 
Ectodermal Dysplasia) by cDNA microarray hybridization 
experiments carried out to identify candidate genes for 
EDA-specific gene expression [30]. In this study in the 
attempt to verify whether ZNF216 could have a role in 
the EGFR signaling and in its biological outcomes, we 
set out to characterize the correlation between the EGFR 
and ZNF216 proteins in human cancer and to demonstrate 
whether a linkage between the EGFR-induced effects and 
ZNF216 expression/function does exist. Understanding the 
dynamics of this molecule and EGFR will be crucial in 
identifying potential new targets.
RESULTS
ZNF216 and EGFR expression in human cancer 
cell lines 
ZNF216 is expressed in brain, hearth, colon, 
spleen, kidney, liver, small intestine, placenta, lung and 
peripheral blood leukocyte but highly expressed in skeletal 
muscle [25, 26, 31]. However, no information related 
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to ZNF216 expression compared to EGFR expression 
in human cancer cell lines was available. A panel of five 
human tumor cell lines differently expressing EGFR was 
tested for ZNF216 and EGFR expression by RT-PCR and 
Western blotting.
RT-PCR analysis revealed that the ZNF216 mRNA 
was variably expressed among the cell lines (Figure 1A) 
with the highest level of expression found in melanoma 
cell line MDA-MB-435 weakly expressing EGFR and the 
lowest levels shown in breast carcinoma cell lines T-47D 
and HBL-100 moderately expressing EGFR mRNA 
[32] A431 cell line showed the highest level of EGFR 
gene expression, paralleled by a very low expression of 
ZNF216 mRNA. The ZNF216 protein levels detected on 
Western blotting (Figure 1B) were almost consistent with 
the pattern observed at the mRNA levels. Moreover, we 
selected three primary prostate cancer cell lines, LNCaP, 
PC3 and DU145, which are widely used and representative 
Figure 1: ZNF216 and EGFR expression in human cancer cell lines. (A) ZNF216 and EGFR mRNA levels were detected in 
RNA samples from three human breast carcinoma (T-47D, HBL-100, MDA-MB-231), one human melanoma (MDA-MB-435) and one 
human epidermoid carcinoma (A431) cell lines, and analyzed by RT-PCR assay. The histogram describes the observed mRNA expression 
of ZNF216 and EGFR normalized with 18S in MDA-MB-435, T-47D, HBL-100, MDA-MB-231 and A431 cell lines. Results are 
representative of three independent experiments. (B) ZNF216 and EGFR protein levels were detected by Western blotting in MDA-MB-435, 
T-47D, HBL-100, MDA-MB-231 and A431 cell lines. β-actin was used as loading control. Results are representative of three independent 
experiments. (C) ZNF216 and EGFR mRNA relative expression levels were detected in RNA samples from LNCaP (androgen-dependent), 
PC3 and DU145 (androgen-independent) prostate cancer cell lines by quantitative Real Time PCR. The data are representative of three 
independent experiments.
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of advanced and highly tumorigenic prostate cancer to 
characterize the correlation between EGFR and ZNF216 
expression through a Real-Time quantitative RT-PCR 
analysis [33–36]. LNCaP cell line, although isolated from 
a lymph node metastasis, represents a well differentiated 
and androgen responsive prostate carcinoma. As shown 
in Figure 1C DU145 cells showed the highest level of 
expression of ZNF216 mRNA. LNCaP cells expressed an 
intermediate level of ZNF216 mRNA while in PC3 cell 
line was detected the lowest expression level of ZNF216 
transcript. On the other hand, PC3 cell line showed the 
highest level of EGFR expression compared to DU145 and 
LNCaP, confirming previously published results [37].
Thus, an inverse correlation between endogenous 
ZNF216 and EGFR level of expression was observed in 
these cell lines and is in accordance with those shown in 
prostate cancer cell lines.
ZNF216 expression in NIH3T3 cells 
overexpressing ErbB receptors
To investigate the mechanism for a possible 
correlation between EGFR and ZNF216 expression 
we moved our attention on a model system consisting 
of fibroblast cell line stably expressing human EGFR, 
previously described (NIH3T3-EGFR) [38] and transfected 
it with a human ZNF216 cDNA (NIH3T3-EGFR/ZNF216).
Total RNA was extracted from these cell lines and 
the expression of ZNF216 genes was evaluated through 
semiquantitative RT-PCR assay. The results of RT-PCR 
indicated that ZNF216 transcript was not detected in 
parental cell line NIH3T3wt and a low but detectable level 
of expression was seen in NIH3T3-EGFR (Figure 2, lanes 
1 and 2). Moreover, in efforts to investigate whether other 
ErbB receptors, namely ErbB2, ErbB3 and ErbB4, were 
correlated to the expression of ZNF216 gene, we carried 
out an RT-PCR analysis in NIH3T3 overexpressing ErbB2, 
ErbB3 and ErbB4 genes in which the up-regulation of single 
ErbB receptor was validated when compared with NIH3T3 
controls through Western blotting analysis (data not shown).
As shown in Figure 2, ZNF216 gene was expressed 
in all the cell lines analyzed with the strongest ZNF216 
expression shown in NIH3T3-ErbB4 overexpressing cells 
(Figure 2, lane 5), thus suggesting that ErbB receptors 
could be involved in regulating ZNF216 expression.
Ectopic expression of ZNF216 protein
In order to investigate the role of ZNF216 
overexpression in EGF-induced cellular signal 
transduction, the pF-hZNF216 construct, containing the 
Flag epitope, was used to stably transfect the NIH3T3wt 
cell line and NIH3T3 cells overexpressing the EGFR 
gene (Figure 3). To ascertain whether the zeocin-resistant 
clones were able to express ZNF216 protein, Western 
blotting (Figure 3A) and immunoprecipitation (Figure 3B) 
analyses with anti-Flag-M2 were performed. As shown 
high amounts of ZNF216 protein are present in NIH3T3wt 
and NIH3T3-EGFR transfected with the pF-hZNF216 
construct compared with respective parental cell lines. 
Activation of the EGFR is required for  
EGF-induced ZNF216 expression
First, in the attempt to verify whether ZNF216 
expression was regulated by EGF treatment, we 
Figure 2: ZNF216 mRNA expression in NIH3T3 transfectant cell lines expressing individual ErbB receptors. ZNF216 
mRNA expression levels were detected in RNA extracted from NIH3T3 overexpressing individual ErbB receptors by RT-PCR assay. The 
expression level of 18S transcript was determined as a loading control. pF-hZNF216: expression vector containing the pF-hZNF216 cDNA 
(kindly provided by Dr. Watanabe). Data are representative of three independent experiments.
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examined the activation status of the EGFR by Western 
blotting analysis and the ZNF216 mRNA expression by 
semiquantitative RT-PCR, both in NIH3T3-EGFR and 
in NIH3T3-EGFR/ZNF216 cells. A time course study 
of EGFR phosphorylation in NIH3T3-EGFR cells was 
carried out showing a fast kinetics of activation at 15 min 
of treatment compared to the unstimulated cells, remaining 
stable after 30 min and 1 h and decreasing thereafter 
(Figure 4A, left). In NIH3T3-EGFR/ZNF216 cells EGFR 
activation increased at 15 min, slightly decreased at 30 
min reached a peak after 1 h of EGF treatment, and then 
decreased again at 3 h (Figure 4A, right).
A low but detectable level of expression of ZNF216 
mRNA was observed in serum starved NIH3T3-EGFR. An 
immediate early activation of ZNF216 transcription was 
observed at 1 h after EGF treatment that decreased after 
3 h and longer (up to 24 h) (Figure 4B, left). A similar 
trend was shown in NIH3T3-EGFR/ZNF216 (Figure 4B, 
right), in according with the EGFR phosphorylation 
behaviour/activity. However, interestingly, a second peak 
of ZNF216 mRNA induction was observed after 24 h of 
EGF treatment.
To further examine the involvement of EGFR 
phosphorylation in the regulation of ZNF216 expression, 
NIH3T3-EGFR/ZNF216 cells were treated with the EGFR 
small molecule tyrosine kinase inhibitor Gefitinib. The 
results obtained clearly indicated that the expression of 
ZNF216 was no longer increased under co-treatment with 
EGF and Gefitinib in parallel with the complete abrogation 
of EGFR phosphorylation (Figure 5), thus suggesting 
that these events might be coupled. Altogether these 
results indicate that EGF treatment can result in EGFR 
activation and consequentially in an increased expression 
of ZNF216.
EGF-dependent nuclear translocation of EGFR 
and ZNF216
It was reported that the EGFR can be activated and 
then translocated into the nucleus as a transcriptional 
activator, and that this nuclear translocation of the EGFR 
is highly correlated with malignancy [12]. Therefore, in 
a first series of experiments, to examine whether EGF 
treatment could influence the intracellular localization of 
EGFR and ZNF216 in NIH3T3 overexpressing both EGFR 
and ZNF216 proteins, we carried out a Western blotting 
analysis on cytosolic and nuclear fractions prepared 
from cells serum starved for an overnight followed by 
a 5, 15 and 30 min incubation with EGF (50 ng/ml). 
In EGF treated NIH3T3-EGFR cells the EGFR appeared 
mostly and markedly phosphorylated in the cytosolic 
fraction than in the nuclear fraction (Figure 6A, upper 
Figure 3: Ectopic expression of ZNF216 protein. (A) NIH3T3wt cells and NIH3T3-EGFR cells stably expressing EGFR, were 
transfected with expression vector containing the pF-hZNF216 cDNA (NIH3T3wt-ZNF216, NIH3T3-EGFR/ZNF216) tagged at its 
N-terminus with a Flag epitope. (B) NIH3T3-EGFR and NIH3T3-EGFR/ZNF216 cells were subjected to immunoprecipitation/Western 
blotting assay using the indicated antibodies. Results are representative of two independent experiments.
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panel). Interestingly, in NIH3T3-EGFR/ZNF216, EGF 
treatment induced an increase of phosphorylated EGFR 
in the cytosolic fraction and also in the nuclear fraction, 
compared to NIH3T3-EGFR cells.
Thus, these results indicate that in the presence 
of ZNF216 overexpression, phosphorylated EGFR 
translocates into the nucleus. Moreover, this result 
suggests that the ligand-activated EGFR did not 
undergo the endocytosis degradation process, but went 
through the nuclear pathway to probably induce gene 
transcription.
It has been previously shown that ZNF216 protein 
is localized largely in the cytoplasm and to a lesser extent 
in the nucleus [22]. In an attempt to verify the effect 
of EGF treatment on ZNF216 cellular localization in 
NIH3T3-EGFR/ZNF216 we carried out a Western blotting 
analysis by using an anti-Flag antibody. The staining of 
ZNF216 was almost intense in the cytosolic fraction of 
unstimulated cells but strongest after EGF treatment, with 
a stronger signal after 15 and 30 min of EGF treatment 
compared to the nuclear fraction of unstimulated cells and 
after 5 min of EGF treatment (Figure 6A, lower panel). 
Therefore, these results demonstrate that EGF is able to 
stimulate increased expression of ZNF216 and its nuclear 
translocation in a time-dependent manner. 
To further confirm the results obtained in the 
NIH3T3 murine model cell line, we moved our interest 
on human epidermoid carcinoma cell line A431 that 
endogenously overexpresses the EGFR. We treated 
starved A431 cell line and A431 cell line transiently 
transfected with pF-ZNF216 with EGF for 30 min. Thus, 
we carried out a Western blotting analysis on cytosolic 
and nuclear fractions of A431 and A431/ZNF216 
cell lines and we proved a similar trend compared to 
NIH3T3-EGFR and NIH3T3-EGFR/ZNF216. In fact, 
the EGF treatment increased the EGFR phosphorylation 
in A431/ZNF216 cells compared to A431 cells, both 
in the cytosolic fraction and in the nuclear fraction 
(Figure 6B). Moreover, in the nuclear fraction of A431 
cells overexpressing the ZNF216 protein a major amount 
of phosphorylated EGFR was observed after EGF 
treatment compared to the cytosolic fraction, according 
with NIH3T3-EGFR/ZNF216 cell line, suggesting a 
possible migration of activated EGFR into the nucleus 
after EGF binding. Interestingly, after EGF treatment, 
the ZNF216 protein was more expressed in the nucleus 
than in the cytosol of A431/ZNF216 cell line, validating 
the hypothesis that ZNF216 protein migrates into the 
nucleus after EGF treatment along with the activated 
EGFR (Figure 6B).
Figure 4: EGF-induced ZNF216 gene expression correlates with EGFR phosphorylation. NIH3T3-EGFR and NIH3T3-
EGFR/ZNF216 cells, first cultured in medium with 0,2% serum for an overnight and then treated without or with EGF for the time 
indicated, were analysed by (A) Western blotting to evaluate the levels of pEGFR protein and (B) by RT-PCR to determine the levels of 
ZNF216 transcript. β-actin and 18S were used as loading control. Results are representative of two independent experiments.
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Figure 5: Effect of Gefitinib on EGF-induced ZNF216 protein expression. The NIH3T3-EGFR/ZNF216 cells were cultured in 
medium with 0,2% serum for an overnight, then exposed to EGF alone or in combination with Gefitinib (1 μM) for 24 h and lysed. Whole-
cell extracts were analysed by Western blotting using antibody for EGFR, pEGFR and ZNF216. μ-actin immunoreactivity was used as a 
loading control. RP-ZNF216: Recombinant Protein ZNF216. Results are representative of two independent experiments.
Figure 6: Subcellular localization of activated EGFR in NIH3T3-EGFR and A431 cell lines overexpressing ZNF216 
protein after EGF treatment. (A) NIH3T3-EGFR and NIH3T3-EGFR/ZNF216 cells were cultured in medium with 0,2% serum for 
an overnight, left unstimulated (0) or stimulated for 5, 15 and 30 min with 50ng/ml EGF and then fractionated into nuclear and cytosolic 
compartments for Western blotting analysis. The membrane was first probed with anti-phosphotyrosine (p-Tyr, upper panel), stripped and 
reprobed with anti-EGFR (middle panel) antibody. Western blots, performed by antibody against the cytoplasmic protein β-actin indicated 
that the extracts are virtually free from cross contamination. Western blotting with the anti-Flag antibody to assess the cellular localization 
of ZNF216. Results are representative of three independent experiments. (B) A431 and A431/ZNF216 cells were treated for 30 min with 
50ng/ml EGF and then fractionated into nuclear and cytosolic fractions for Western blotting analysis. Western blots, performed by antibody 
against the cytoplasmic protein β-actin and against fibrillarin, nuclear protein, indicated that the extracts are virtually free from cross 
contamination. Results are representative of three independent experiments.
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Finally, the EGFR and ZNF216 subcellular 
localization was evaluated with an immunofluorescence 
assay (Figure 7), in the absence and presence of EGF 
(50 ng/ml, 30 min, 6 and 24 h) by staining with anti-
EGFR and anti-Flag antibodies. Before stimulation, 
EGFR (green) was clearly localized and homogenously 
distributed to the membrane, while ZNF216 (red) was 
consistently distributed in the cytoplasm. EGF treatments 
induced protein redistribution: after 30 min EGFR and 
ZNF216 co-localized (yellow signals) in the perinuclear 
region, but after 6 h a significant fraction of ZNF216 was 
detected in the nucleus. This result supports the hypothesis 
of a possible cooperation between EGFR and ZNF216 
protein, and even though we failed to demonstrate 
a physical association with co-immunoprecipitation 
experiments (data not shown) further studies are necessary 
to clarify this mechanism. 
After 24 h, the distribution and localization of EGFR 
and ZNF216 was similar to the control. The image revealed 
the presence of apoptotic cells, probably due to a cytotoxic 
effect of the treatment. After 24 h of treatment with EGF, 
the morphology of NIH3T3-EGFR/ZNF216 cells showed 
cell membrane blebbing, pyknotic nuclei with chromatin 
condensation, and formation of apoptotic bodies.
Stimulation of EGFR-dependent gene activation 
by ZNF216 in NIH3T3 cells overexpressing 
EGFR
The successive step was to evaluate in which way 
ZNF216 overexpression could regulate/modulate the 
signaling cascades triggered by EGFR. Phosphorylation of 
EGFR by EGF led to the activation of the MAPK and PI3K/
Akt pathways that play an important role in cell proliferation 
and survival. NIH3T3-EGFR and NIH3T3-EGFR/ZNF216 
cells were serum starved for an overnight followed by a 5, 
15 and 30 min incubation with EGF (50 ng/ml). The results 
obtained showed an EGF-induced time-dependent activation 
of MAPK (Figure 8A) and Akt (Figure 8B) in NIH3T3-
EGFR/ZNF216. The phosphorylation of Akt in NIH3T3-
EGFR/ZNF216 cells was relatively long lasting when 
compared with the Akt activation in NIH3T3-EGFR cells.
Biological effects of ZNF216 overexpression
So far we demonstrated that:
1. an inverse correlation does exist between EGFR 
and ZNF216 molecules, both at mRNA and protein levels;
Figure 7: Immunofluorescence localization of EGFR and ZNF216. NIH3T3-EGFR/ZNF216 cells were cultured in medium with 
0,2% serum for an overnight, left unstimulated (C) or stimulated for 30 min, 6 and 24 h with 50ng/ml EGF. EGFR is visualized as green 
fluorescence, ZNF216 as red fluorescence and DAPI positive nuclei as blue fluorescence. The merge of the three colors is reported in the 
right column. Arrows show apoptotic cells. Magnification is 40X. Images are representative of five separate experiments
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Figure 8: Effect of EGF on MAPK and Akt activation. NIH3T3-EGFR and NIH3T3-EGFR/ZNF216 cells were cultured in 
medium with 0,2% serum for an overnight, left unstimulated and then treated with EGF (50ng/ml) for the times indicated. Proteins lysates 
were subjected to Western blotting for phosphorylated MAPK and for β-actin (A, upper and lower panel) and for phosphorylated and total 
Akt (B, upper and lower panel). Reaction products were quantified by computer-assisted densitometry. Results are representative of three 
independent experiments.
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2. EGF increased the expression of ZNF216 both 
in the cytosolic and in the nuclear fraction in a time-
dependent manner;
3. in cells overexpressing ZNF216 protein, EGF 
increased EGFR phosphorylation in both the cytosolic and 
the nuclear fraction compared to control cells;
4. a sustained phosphorylation of MAPK and 
Akt was observed after EGF treatment in ZNF216 
overexpressing cells.
Therefore, in the next set of experiments we 
investigated the biological effects of the increased 
phosphorylation of EGFR, MAPK and Akt in cells 
overexpressing the ZNF216 protein.
First, cell cycle analysis was performed to evaluate 
changes in the cell cycle distribution after EGF treatment 
of ZNF216 overexpressing cells. While NIH3T3-EGFR 
cells (Figure 9A) continued to progress into S phase 
after EGF treatment from 24 h (quiescent 6.24%, EGF-
treated 11.7%) to 48 h (quiescent 17.6%, EGF-treated 
39.3%), NIH3T3-EGFR overexpressing ZNF216 protein 
(Figure 9B) displayed a progression toward S phase after 
24 h of EGF treatment (quiescent 6.75%, EGF-treated 
13.7%) but a loss of S phase cells from 20% in quiescent 
cells to 12.8% after 48 h of EGF-treatment. In parallel, 
NIH3T3-EGFR/ZNF216 cells accumulate in G1 phase 
more than NIH3T3-EGFR after 48 h of EGF-treatment 
(75.8% and 35.7%, respectively) (Figure 9). 
Therefore, these results showed that EGF treatment 
caused in NIH3T3 overexpressing ZNF216 protein a 
decrease in the S-phase population with accumulation of 
cells in the G1 phase of the cell cycle. 
ZNF216-induced apoptosis in NIH3T3-EGFR 
cells in vitro 
ZNF216 was shown to inhibit Tumor Necrosis 
Factor (TNF), IL-1 and TLR4-induced NF-κB activation 
and its overexpression sensitized cells to TNF-induced 
apoptosis. In order to evaluate possible apoptotic effects 
of ZNF216, NIH3T3-EGFR cells overexpressing ZNF216 
protein were treated with 50 ng/mL EGF up to 24 h and 
analysed by TUNEL assay. It was interesting to note that 
in the absence of stimuli no induction of apoptosis was 
displayed; instead, a significantly increased positivity for 
the terminal deoxynucleotidyl transferase (TdT)-mediated 
nick end labeling (TUNEL) was found in NIH3T3-
Figure 9: Cell cycle analysis of NIH3T3-EGFR and NIH3T3-EGFR/ZNF216 cells treated with EGF. NIH3T3-EGFR (A) 
and NIH3T3-EGFR/ZNF216 (B) cells were cultured in medium with 0,2% serum for an overnight, left unstimulated and then treated with 
EGF (50ng/ml) for the times indicated. Cytofluorimetric analysis was performed in cells that are in the different phases of cell cycle. The 
data, representative of three independent experiments, were performed in duplicate.
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EGFR/ZNF216 samples treated with EGF indicative 
of apoptotic cell death (Figure 10). Moreover, besides 
apoptotic nuclei, a number of cells displayed an increased 
amount of cytoplasm and an overall increased size already 
after 30 min EGF treatment in consistence with the 
occurrence of the G1 block detected with flow cytometry 
from 48 h onwards (Figure 9B). To further confirm the 
apoptotic effect of ZNF216 in NIH3T3-EGFR cells and 
overexpressing ZNF216, we investigated the status of 
PARP protein in cells treated with EGF at different time 
points. The results obtained indicated that PARP cleavage 
was evident in cells overexpressing ZNF216 protein from 
15 min and sustained up 24 h compared to NIH3T3-EGFR 
cells (Figure 11), confirming previous results obtained.
DISCUSSION
In this study we demonstrated that the ZNF216 
expression is induced by EGF treatment and that it is 
involved in the regulation of Epidermal Growth Factor 
Receptor (EGFR) tyrosine kinase signaling and biological 
outcomes. The EGFR, also known as ErbB1, is one of 
four members of the ErbBs family of transmembrane 
growth factor receptor with tyrosine kinase (TK) activity, 
and it is activated by a number of ligands, including 
EGF. EGFR controls cell proliferation and survival [39, 
40] and its cellular activity is dysregulated in cancer 
by several mechanisms including gene mutation, gene 
amplification, and protein overexpression [41, 42]. 
Figure 10: EGF-induced apoptosis in NIH3T3-EGFR overexpressing the ZNF216 protein. (A) Immunofluorescence 
labelling of NIH3T3-EGFR and NIH3T3-EGFR/ZNF216 after treatment with 50 ng/ml of EGF for different time intervals (0 min, 30 min, 
1 h, 3 h). (B) The histogram shows the mean percentage ± S.E. of apoptotic cells detected in NIH3T3-EGFR and NIH3T3-EGFR/ZNF216. 
The inset shows an apoptotic cell labelled with TUNEL technique (green fluorescence) or double-labelled with TUNEL plus 6-diamino-
2-phenylindole (DAPI) (blue fluorescence) to counterstain nucleus. Original magnification: 20x. NIH3TR3-EGFR vs NIH3TR3-EGFR/
ZNF216: 0 min p=0.015; 30 min p=3.49x10-9; 1 h p=0.031; 3 h p=0.015.
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Binding of EGF to EGFR activates the tyrosine kinase 
activity of the receptor, resulting in autophosphorylation 
of tyrosine residues in the carboxy-terminal domain 
and in activation of downstream signaling cascades 
that culminate in cell fate decisions [2]. Moreover, after 
autophosphorylation, EGFR is ubiquitinated and targeted 
for internalization, even if the ubiquitin-based mechanism 
has been ruled out as essential for EGFR internalization 
[43]. However, ubiquitination is also thought to act as 
a signal for post-endocytotic processing, leading EGFR 
through the endosomal pathway to either subsequent 
degradation in the lysosome or escape recycling route to 
the plasma membrane [44] where receptor functionality 
is maintained [45].
EGFR is activated, degraded and recycled 
depending to a complex signaling in which time and 
context restrictions (e.g. ligand type, cell density) are the 
leading factors thus, influencing the EGFR-dependent 
biological effects, such as cells’ proliferation, survival, 
adhesion, differentiation, and migration [18]. Thus, EGFR 
aberrant activity and its signaling complexity are crucial 
in the pathogenesis of human cancer. The sophisticated 
regulations of feedback and feedforward loops that 
characterize its signaling processes are worth to be 
extensively studied [46].
ZNF216 is expressed in brain, hearth, colon, spleen, 
kidney, liver, small intestine, placenta, lung and peripheral 
blood leukocyte but highly expressed in skeletal muscle 
[25, 26, 31]. However, no information related to ZNF216 
expression compared to EGFR expression in human cancer 
cell lines was available. Thus, first of all we investigated 
the endogenous expression of this protein in a panel of 
five human tumor cell lines differently expressing EGFR. 
As an initial approach, we tested the mRNA expression 
by RT-PCR analysis. The results obtained revealed that 
the ZNF216 mRNA was variably expressed among the 
cell lines (Figure 1A) with the highest level of expression 
found in melanoma cell line MDA-MB4-35 weakly 
expressing EGFR and the lowest levels shown in breast 
carcinoma cell lines T-47D and HBL-100 moderately 
expressing EGFR mRNA [32]. The ZNF216 protein levels 
detected on Western blotting (Figure 1B) were almost 
consistent with the pattern observed at the mRNA levels. 
The inverse correlation between endogenous ZNF216 and 
EGFR level of expression was also observed in prostate 
cancer cell lines, such as LNCaP, DU145 and PC3 cells.
After these preliminary data, we moved our 
attention from human cancer cell lines model to a murine 
not transformed cell line model, to investigate the role of 
ZNF216 in cancerogenesis, in vitro. In particular, we used 
Figure 11: Effect of EGF on cleaved PARP. NIH3T3-EGFR and NIH3T3-EGFR/ZNF216 cells were cultured in medium with 0,2% 
serum for an overnight, left unstimulated and then treated with EGF (50ng/ml) for the times indicated. Cellular proteins were subjected to 
Western blotting for PARP and β-actin. Results are representative of three independent experiments.
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NIH3T3 cells, which normally express a low number of 
functional EGF receptors (~3 × 103 receptors per cell) [38] 
and extensively used to assess the transforming activities 
of different oncogenes [47]. Our results indicated that 
EGF treatment induced ZNF216 mRNA and protein 
expression both in NIH3T3 cells overexpressing EGFR 
and in NIH3T3-EGFR/ZNF216 cells. In particular, in our 
study we found an early induction of ZNF216 protein 
expression after EGF treatment (Figure 6A). Moreover, 
we showed that ZNF216 induction is dependent from 
EGFR tyrosine kinase activity since Gefitinib treatment 
decreased ZNF216 protein expression in EGF-treated 
NIH3T3-EGFR/ZNF216 cells (Figure 5). Additionally, 
in our study ZNF216 mRNA expression was sustained 
for 1 h (Figure 4B), decreased after 3 h but could still 
be detected after 24 h of EGF only in NIH3T3-EGFR/
ZNF216 cells. Signaling pathways activated by EGFR 
may result in the transcription of a set of “immediate 
early genes” (IEGs) [48, 49], whose induction does 
not require protein synthesis and thus involves latent 
transcriptional activators already present in cells [50, 51]. 
The proteins encoded by IE genes are transcription factors 
or signaling pathway regulators which can further affect 
cellular gene expression profiles and hence promote 
phenotypic changes, such as those observed in cancer. 
In the study of Schmahl et al., Znf216 (Zfand5) has been 
found to be an immediate early gene (IEG) involved, as 
a transcription factor, in neonatal survival in mice [23]. 
The induction of ZNF216 protein expression after EGF 
treatment for 30 min (Figure 6) is in accordance with 
previous studies characterizing the ZNF216 as an IEG 
induced by RTKs, such as PDGFR [23]. In fact, it has been 
previously observed that EGFR activation induced many 
of the same genes as PDGFR, even if at a lower level of 
induction [52]. The transcriptional program induced by 
growth factor stimulation involved distinct classes of 
genes: immediate early genes and secondary response 
genes that are induced later than immediate early genes 
[53]. Therefore, the induction kinetics of Znf216 gene in 
response to EGF treatment gains insight into the possible 
functional differences of Znf216, as an immediate early 
gene and as a secondary response gene.
Computational analysis allows us to find out some 
binding sites for the transcription factor Early growth 
response-1 (Egr1) into the Znf216 gene promoter. Egr1 
encodes a zinc finger transcription factor that exemplifies 
a group of immediate early response genes, since a variety 
of growth factors, cytokines, rapidly and transiently 
induce its expression. The induced EGR1 in turn binds 
to the EGR response element in the promoter regions of 
growth factors and cytokines and up-regulates these genes. 
Thus, EGR1 may function as a converging point for many 
signaling pathways [54]. Among the growth factors, 
EGF has been shown to strongly induce Egr1 expression 
through MAPK-ERK pathway [54, 55]. It has been shown 
that Znf216 is induced at a transcriptional level by TNF-α 
or IL-1 in fibroblasts or macrophages [31] suggesting that 
is a part of a negative feedback loop aimed at limiting 
pro-inflammatory signaling likely by inhibiting NF-kB 
activation in response to TNFR or IL-1/TLR signaling 
in epithelial cells lines [26]. Here we demonstrated that 
Znf216 is an EGF-induced gene.
Moreover, our results indicated that EGF stimulation 
increases the nuclear localization of ZNF216 protein in 
NIH3T3 cell line transfected with ZNF216 more than in 
the cytoplasmic fraction, suggesting a possible role played 
by this protein in the nuclear compartment. Concurrently 
pEGFR, in according with literature, increases both in the 
cytoplasm and in the nucleus after EGF stimulation, but 
this is clearly more evident in NIH3T3-EGFR/ZNF216 
than in NIH3T3-EGFR cell line, suggesting a possible role 
of the ZNF216 protein to act with phosphorylated EGFR in 
the nucleus after EGF treatment. By immunofluorescence 
we demonstrated that EGFR and ZNF216 co-localized in 
the perinuclear region, but after 6 h a significant fraction 
of ZNF216 was detected in the nucleus. In the context of 
membrane receptor tyrosine kinases signaling, different 
zinc finger proteins are involved. Indeed, Enigma is able 
to bind to the insulin receptor and the zinc finger protein 
ZPR1 to the EGFR [56].
Sorting of activated EGFR for lysosomal degradation 
(and therefore attenuation of signaling) or recycling 
to the plasma membrane (associated with prolonged 
signaling) is fundamental to the regulation of EGFR 
signaling. However, alternative fates for activated EGFRs 
are emerging, including traffic to the nucleus [12, 57]. 
Nuclear EGFR has two identified functions in the 
nucleus: 1) as a transcription factor and 2) in the direct 
phosphorylation of Proliferating Cell Nuclear Antigen 
(PCNA). As a transcription factor, EGFR has been shown 
to interact with STAT3 and E2F1 to mediate transcription of 
cycD1, iNOS, B-myb and Aurora kinase A [58–61, 12, 16]. 
In our study, the observation that nuclear EGFR is 
phosphorylated at its autophosphorylation sites indicates 
that kinase activity of EGFR is present within nucleus and 
suggests that this kinase activity may be relevant for the 
function of nuclear EGFR [62]. The fact that expression 
of ZNF216 is itself under the control of EGFR, suggests 
that ZNF216 could be involved in the negative feedback 
regulation of EGFR activation. 
Our results indicate that ZNF216 overexpression 
sensitizes to apoptosis the NIH3T3/EGFR/ZNF216 cells 
thus antagonizing the effect of activated EGFR-mediated 
survival in control cells that do not overexpress the 
ZNF216. The role of ZNF216 in induction of apoptosis has 
been well established by Huang et al. who demonstrated 
that although ZNF216 mimics A20 in terms of NF-kB 
regulation, these two molecules have opposing effects as 
regulators of cell viability. Indeed, whereas A20 enhances 
viability of most cell types, overexpression of ZNF216 has 
been shown to sensitize cells to TNF-induced apoptosis 
[26] in according with our results. However, this is in 
Oncotarget74960www.impactjournals.com/oncotarget
disaccording with the over activation of Akt observed in 
NIH3T3-EGFR/ZNF216 after 30 min of EGF treatment, 
the same time during which we could observe the highest 
percentage of apoptotic cells (Figure 10B). In this regard, 
a report has proven that manipulation of the NF-kB, c-Jun 
N-terminal kinase, or p38 MAPK signals switches leukemia 
cells from a proliferative to an apoptotic phenotype leading 
highly proliferative cells to die rapidly [63]. Moreover, the 
recruitment of PI3K/Akt and other survival pathways has 
been demonstrated both in primary cells and leukemia 
cell lines in response to TRAIL treatment in spite of the 
induction of apoptosis [64–66]. The fate of the cell would 
depend on the intensity, kinetics, and synergy of agonistic 
or antagonistic pathways activated. Thus, we suggest that 
mechanisms downstream of Akt may interfere with the pro-
survival effect induced by EGF.
MATERIALS AND METHODS
Cell culture, transfections and stimulation by 
growth factors
Human epidermoid carcinoma (A431), human 
breast carcinoma (T-47D, HBL-100, MDA-MB-231), 
and human melanoma (MDA-MB-435) cells, were 
maintained in DMEM supplemented with 10% Foetal 
Bovine Serum (FBS). The NIH3T3 wild type fibroblasts 
(NIH3T3wt) and NIH3T3 stably overexpressing human 
EGF receptor (NIH3T3-EGFR) and other receptors of the 
ErbB family (NIH3T3-ErbB2, NIH3T3-ErbB3, NIH3T3-
ErbB4), were grown in DMEM containing 10% Foetal 
Calf Serum (FCS). These transfectants have previously 
been characterized and are known to express individual 
ErbB receptors in the range of 0.6–3 × 106 molecules/cell 
[67–70].
The three human prostate carcinoma cell lines 
used in this study, were differentially cultured: the PC3 
(androgen-independent) cell line was maintained in 
DMEM-F12 supplemented with 10% FBS, DU145 
cell line (androgen-independent) was grown in DMEM 
containing 10% FBS and the LNCaP cell line (androgen-
dependent) was grown in RPMI with 10% FBS, 10 mM 
Hepes and 1 mM Sodium pyruvate. Gefitinib (ZD1839) 
was provided by AstraZeneca (Macclesfield, UK). Stock 
solutions were prepared in DMSO and then stored at 
−20°C. For the experiments the cell lines were treated 
with or without Gefitinib at a concentration of 1 µM, 
corresponding to serum concentration usually reported in 
clinical trials.
NIH3T3wt, NIH3T3-EGFR cells were stably 
transfected with ZNF216 expression plasmid pF-hZNF216 
(gift of K. Watanabe) using the NucleofectorTM kit (Lonza, 
Cologne, Germany) according to the manufacturer’s 
protocol. We used 6 µg of pF-hZNF216 expression vector, 
which carries a zeocyn resistance gene [22]. Briefly, 
1 × 106 cells were pelleted and re-suspended in 100 µl 
of solution R, and electroporated with 6 µg of DNA. The 
electroporated cells were re-suspended in 500 µl RPMI 
transferred into the 6-well plated and incubated for 24 h 
at 37°C and 5% CO2. One day post-transfection, the cells 
were trypsinized and re-plated in DMEM containing 
10% serum and Zeocin (Life Technologies, Carlsband, 
CA, USA) for selection of stably transfected cells. Drug-
resistant colonies were expanded to generate clonal cell 
lines. Clones were assayed for the expression of ZNF216 
by immunoblotting using anti-Flag antibody.
A431 cells (3 × 105) were transient transfected 
with 4 µg of pF-hZNF216 expression vector using 10 µl 
of Lipofectamine 2000 (Life Technologies) in Opti-
MEM reduced serum medium (GIBCO) for 4 h and then 
grown in DMEM at 0.2% FBS. After 24 h the cells were 
stimulated with the addition of 50 ng/ml of EGF (Sigma-
Aldrich, St. Louis, MI, USA) for 30 min and then washed 
once with Phosphate Buffered Saline (PBS) and used for 
nuclear and cytoplasm fractioning.
Anti-ZNF216 polyclonal antibody production
On the basis of the ORF coding for hZNF216, 
two oligonucleotide primers were designed as 
follows: primer F (carrying a 5′ recognition site for 
the restriction enzyme BamHI, shown underlined), 
5′-CGGGATCCATGGCTCAGGAGACTAACC-3′ (sense) 
and primer R (carrying a 5′ recognition sites for 
the restriction enzyme EcoRI, shown underlined), 
5′-CGGAATTCTTATATTCTCTGAATTTTTTCAGC-3′ 
(antisense). PCR was performed to obtain the hZNF216 
gene; in addition to the template, pF-hZNF216 kindly 
provided from Dr. Ken Watanabe, and the primers (F and 
R), the 50 µl reaction mixture contained 0.2 mM of each 
dNTP, Pfu DNA polymerase buffer and 2.5 units of Pfu 
DNA polymerase (Promega, Madison WI, USA).The 
PCR reaction was subjected to 30 cycles of amplification 
(60 s at 94°C, 60 s at 55°C and 60 s at 72°C). Both the 
amplified products and the pGEX-4T-1 expression vector 
(Life Technologies) were digested with BamHI and 
EcoRI. The PCR fragment encompassing the complete 
hZNF216-coding region was ligated into the restricted 
pGEX-4T-1 vector by using T4 DNA ligase (Boehringer 
Mannheim, Ingelheim Germany); the resulting plasmid 
was designated pGEX-hZNF216. An overnight culture of 
E. coli BL21pLys cells transformed with pGEX-hZNF216 
was diluted 1:10 and allowed to grow until the OD600 
reached 0.4. To induce gene transcription, isopropyl β-D-
thiogalactoside was added to a final concentration of 1 mM 
and the incubation was extended for further 5 h. The cells 
were collected by centrifugation (10,000 × g for 15 min), 
suspended in PBS and disrupted with cold sonication. The 
hZNF216 recombinant protein was cleaved by treatment 
with thrombin, as described by the manufacturer (Life 
Technologies). The purity of the protein was analysed 
using SDS/PAGE (12.5% polyacrylamide gels), and 
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proteins were detected with silver staining. PBS containing 
100 µg of recombinant hZNF216 was emulsified with 
Freund’s complete adjuvant (1:9, v/v) and subsequently 
injected into a New Zealand White rabbit. After primary 
immunization, the animal was given 500 µl of emulsion 
containing 100 µg of antigen on days 14, 21 and 42; it 
was then bled 42 days later, and the antiserum was then 
collected and used for immunoblotting.
Immunocytofluorescence
To identify the subcellular localization of ZNF216 
after EGF treatment, NIH3T3-EGFR cells were stably 
transfected with ZNF216/FLAG-tagged plasmid 
(NIH3T3-EGFR/ZNF216). NIH3T3-EGFR/ZNF216 
cells were seeded in 24-well plates containing 12 mm 
round glass coverslips and grown overnight in DMEM 
10% FCS. The samples were washed twice and serum-
starved for 20 h in DMEM with 0.2% FCS. Samples 
were then stimulated through the addition of 50 ng/ml of 
EGF (Sigma-Aldrich) and then incubated at 37°C for the 
time intervals indicated. After two washes in PBS cells 
were fixed with freshly prepared 4% paraformaldehyde 
in PBS (10 min at room temperature), washed in PBS 
(5 min), and reacted with monoclonal anti-EGFR 
antibody (1:50) (Dako, Carpenteria CA, USA) and 
polyclonal anti-Flag antibody (1:200) (Cell Signaling 
Technology, Beverly, MA, USA) in 150 mM NaCl, 5mM 
EDTA, 50 mM Tris-HCl, pH 7.4, 0.05% NP-40, 0.25% 
carragenin Lambda gelatin, 0.02 NaN3 (NET gel) for 
2 h at room temperature. After several washes, cells were 
incubated with anti-rabbit IgG Alexa Fluor®488 conjugate 
(diluted 1:500) and anti-mouse IgG Alexa Fluor®568 
conjugate (diluted 1:500) in NET gel for 45 min at room 
temperature. After one wash with NET gel and one with 
PBS, samples were stained (5 min) with PBS 0.5 mg/ml 
DAPI, then washed in PBS, dried with ethanol (70%, 
90%, 100%) and finally mounted in glycerol containing 
1,4-diazabicyclo[2.2.2]octane to minimize fading. 
Negative controls were represented by samples incubated 
with the secondary antibodies only. Slides were observed 
with a i50 microscope (Nikon) and images were acquired 
with a Cool-SNAPcf digital CCD camera (PhotoMetrics, 
Huntington Beach, CA, USA). Digital acquisition, 
processing and analysis of fluorescence were performed by 
Meta Image Series 7.5 (MetaMorph, Metafluor, MetaVue) 
software obtained from Molecular Devices.
Immunoprecipitation and Western blotting
The cells with or without growth factor treatment 
were washed with ice-cold Ca2+, Mg2+-free PBS and lysed in 
freshly prepared lysis buffer [2mM Na3VO4, 4 mM sodium 
pyrophosphate, 10 mM sodium fluoride, 50 mM HEPES 
pH 7.9, 100 mM NaCl, 10 mM EDTA, 1% Triton X-100, 
2 mg/ml leupeptin, 2 mg/ml aprotinin, 1 mM PMSF]. 
Cell lysate were cleared with centrifugation at 12.000 
rpm for 20 min. Protein concentrations were determined 
using the BCA protein assay (Thermo Fisher Scientific, 
Waltham, MA USA). For the immunoprecipitation, 500 
mg of protein were incubated at 4°C overnight with anti-
Flag antibody (1:50) (Cell Signaling Technology). Then, 
50 ml of 10% protein-A Sepharose (GE Healthcare Europe, 
Chalfont St. Giles, UK) were added and incubated at 4°C 
for 3 h. The precipitates were washed three times with ice-
cold immunoprecipitation buffer [10 mM Tris-HCl pH 
7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.2 mM 
Na3VO4, 0.2 mM PMSF, 1% Triton X-100, 0.5% Nonidet 
P-40]. All samples were then boiled for 5 min in sample 
buffer containing 0.5 M Tris-HCl, pH 6.8, 10% glycerol, 
2% SDS, 0,1% bromophenol blu, 5% β-mercaptoethanol. 
Samples were then run on SDS-PAGE. Resolved proteins 
were electrophoretically transferred to PVDF membrane 
(Bio-Rad Laboratories, CA, USA). The membranes were 
incubated in blocking buffer for 1 h and then incubated 
with antibodies against the following proteins: anti-Flag, 
anti-phospho-p44/42 MAPK, anti-phospho-Akt, anti-Akt, 
anti-phospho-EGFR (Tyr1068), anti-PARP (Cell Signaling 
Technology); anti-Fibrillarin, anti-EGFR (Santa Cruz 
Biotechnology, CA, USA); anti-PTyr PY20 (Transduction 
Laboratories, KY, USA); anti-β-actin (Sigma-Aldrich) and 
anti-ZNF216. Primary antibodies were detected through 
peroxidase-conjugated relative secondary antibodies. 
Finally, the immune complexes were visualized using 
the ECL Western blot detection system (Thermo Fisher 
Scientific).
Cytoplasmic and nuclear fractionation
Cytoplasmic and nuclear extracts were prepared 
from NIH3T3-EGFR, NIH3T3-EGFR/ZNF216 and 
A431 cells transfected with pF-hZNF216, serum-
starved for 20 h in DMEM with 0.2% FCS and treated 
with 50 ng/ml of EGF (Sigma-Aldrich) for the time 
intervals indicated. These cells, after washing with 
cold PBS, were re-suspended in lysis buffer [10 mM 
HEPES (pH 7.4), 10 mM KCl, 2 mM MgCl2, 0.1 mM 
EDTA] with protease and phosphatase inhibitors, 
and incubated on ice for 10 min. Nonidet P-40 was 
added to the cells to a final concentration of 0.5% 
followed by mixing and centrifugation at 1,000 × g 
for 5 min at 4°C, and the supernatant was saved as a 
cytosolic extract. Nuclear extracts were prepared by 
re-suspending the pellets in 15 ml of 50 mM HEPES 
(pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM 
EDTA, 10% glycerol, and protease and phosphatase 
inhibitors. Proteins were extracted through agitation for 
20 min at 4°C, the insoluble fraction was removed by 
centrifugation at 13,000 × g for 10 min. The supernatant 
was stored as a nuclear extract. Proteins from nuclear 
and cytoplasmic fractions were then analysed through 
Western blotting analysis.
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RNA extraction, reverse transcription-
polymerase chain reaction (RT-PCR) and  
real-time quantitative PCR (qRT-PCR)
Total RNA was extracted from cell lines using 
Trizol Reagent (Life Technologies) according to the 
manufacturer’s instructions. All RNA samples were 
examined as to their concentration, purity and integrity 
based on absorbance ratio at 260/280 nm using NanoDrop 
2000 c UV-Vis Spectrophotometer (Thermo Fisher 
Scientific). Overall sample integrity was confirmed by 
denaturing formaldehyde agarose gel electrophoresis, 
showing sharp and intense 18 S and 28 S ribosomal RNA 
bands with a total absence of smears. Two-step RT-PCR 
was performed using the QuantiTect Reverse Transcription 
Kit (QIAGEN GmbH, Hilden, Germany) for cDNA 
synthesis according to the manufacturer’s recommendations 
and cDNAs were stored at −20°C until use.
Primers for human ZNF216, human EGFR 
and housekeeping genes 18S, were designed using 
Gene Works software (Intelli Genetix, Inc., Mountain 
View, CA, USA) and Allele ID, PREMIER Biosoft 
International (Corina Way Palo Alto CA, USA). The 
RT-PCR reactions were performed using 1 ml (of 20 ml) 
of cDNA template amplified in a total volume of 20 ml, 
containing 200 mmol/L each of all four deoxynucleoside 
triphosphates, 2 mmol/L each of specific primers and 1unit 
of Taq DNA Polymerase (QIAGEN GmbH). Quantitative 
Real-Time PCR assay was carried out in an Eppendorf 
Master cycler EP RealPlex (Eppendorf AG, Hamburg, 
Germany). For all reaction cDNA templates 1 ml was 
used in a 20 ml Real Time quantitative PCR amplification 
system of SYBR Green real Master Mix kit (Promega) 
according to the manufacturer’s recommendations. The 
data obtained have been converted into correct input 
files, according to the requirements of the software and 
analyzed using VBA applet and BioGazelle for the gene 
of interest. 
Cell cycle analysis 
The number of cells in each phase of the cycle was 
evaluated by means of flow cytometry after Propidium 
Iodide (PI) staining of ethanol-fixed cells. The samples 
were serum-starved for 20 h in DMEM with 0.2% FCS, 
treated with 50 ng/ml of EGF (Sigma-Aldrich) and then 
incubated for the time intervals indicated. The 5 × 105 cell 
samples were vortexed in 200 ml of PBS and fixed with 
500 ml of ice-cold 70% ethanol at 4°C for at least 2 h. 
The cells were then centrifuged, washed once in PBS, re-
suspended in 500 ml PBS and incubated in the dark at 
room temperature for 30 min in the presence of 100 mg/ml 
RNAse and 20 mg/ml PI. The PI fluorescence of 
individual nuclei was measured using FAC Scan (Becton-
Dickinson, San Josè, CA, USA). The proportions of cells 
in the G0/G1, S and G2/M phases of the cell cycle were 
automatically calculated by the Lysis II analysis software 
(Becton-Dickinson).
Immunofluorescent staining of DNA strand 
breaks (TUNEL)
The TUNEL assay detects single or double 
DNA strand breaks by means of labelled nucleotides 
polymerized to free 3′-hydroxyl termini in a reaction 
catalyzed by Terminal deoxynucleotidyl Transferase 
(TdT). The NIH3T3-EGFR and NIH3T3-EGFR/ZNF216 
cells grown in 24 well plates were serum starved for 20 h 
in DMEM supplemented with 0.2% FCS. After treatment 
with 50 ng/ml EGF for 30 min, 1 and 3 h, the cells were 
fixed with 4% paraformaldehyde. Samples were incubated 
in a permeabilizing solution (0.1% Triton X-100, 0.1% 
sodium citrate) for 2 min on ice. Deoxyribonucleic acid 
strand breaks were identified with an “In situ cell death 
detection kit” (Boehringer Mannheim, Mannheim, 
Germany) according to the manufacturer’s instructions. 
Slides were counterstained with DAPI (Vectors 
Laboratories, Burlingame, CA, USA), mounted in glycerol, 
and observed with a ZEISS Axioskop light microscope 
equipped with a CoolSNAP video camera (CoolSNAP; 
Photometrics, Tucson, AZ, USA) for acquiring digital 
images. The extent of DNA fragmentation was quantified 
through direct visual counting of labelled nuclei at 40× 
magnification. At least three monolayers per sample were 
examined, and apoptotic cells were scored out of a total 
of 100 cells. Positive control samples consisted of cells 
treated with deoxyribonuclease I at 2–5 mg/ml for 10 min 
at room temperature, while negative control samples were 
performed omitting TdT in the incubation mixture.
CONCLUSIONS
The negative correlation observed between EGFR 
and ZNF216 could imply a functional interplay between 
these two genes. In this model, the lack or functional loss of 
ZNF216 should potentiate the survival induced by EGFR. 
A more thorough understanding of the EGFR signaling 
pathway will facilitate the future success of clinically used 
anti-EGFR agents and the development of novel therapies 
that target the EGFR pathway. Our results on ZNF216 
functions could have both basic as well as significant 
clinical relevance: (a) this molecular regulator may be 
critical in tumor cell-specific EGFR overexpression, a 
common occurrence in a variety of epithelial tumors; 
and (b) ZNF216 could be a novel therapeutic target, up-
regulation of which could contribute to the degradation of 
EGFR protein leading to reduced clonogenic survival of 
EGFR-addicted cancer cells. In short, the findings paint 
a picture of two molecules, EGFR and ZNF216, that are 
linked and provide a signature for the crosstalk between 
them, offering an additional readout to the potential 
function of ZNF216. However, the results here shown 
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based on the capability of ZNF216 to inhibit EGFR pro-
survival effect could provide a new molecule as a potential 
target for intervention even if future functional studies 
aimed at clarifying the mechanism through which this 
occurs and at analyzing their expression in human cancer 
compared to paired adjacent normal tissues whom clinical 
data is available, are clearly warranted. Understanding 
the dynamics of this receptor, whose signaling is highly 
regulated in both subcellular localization and kinetics by 
several extracellular and intracellular processes, will be 
crucial in identifying potential new targets. Epidemiological 
and further functional in vitro studies are required to 
establish the reliability of EGFR and Znf216 genes as 
possible valid molecular targets in the pharmacological 
strategies aimed at controlling human tumorigenesis.
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